Home Newsfeeds Wedbush Maintains Outperform on Foghorn Therapeutics, Raises Price Target to $20

Wedbush Maintains Outperform on Foghorn Therapeutics, Raises Price Target to $20

Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.

Longeveron Issues Letter To Shareholders Highlighting Corporate Strategy, Clinical Pipeline And 2024 Key Priorities And Goals

By Benzinga Newsdesk

April 8, 8:44 AM

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company's CEO, Wa'el Hashad, issued the following letter to Longeveron

LGVN

Movers
News

What’s Going On With Prestige Weath (PWM) Stock Monday?

By Erica Kollmann

July 10, 12:31 PM

Prestige Wealth, Inc. (NASDAQ: PWM) shares are volatile Monday. The stock has been halted multiple times in early trading. Here's a look at what's going on.

PWM

Sonoco Increases Quarterly Stock Dividend From $0.51 To $0.52 Per Share

By Benzinga Newsdesk

April 17, 10:52 AM

The Board of Directors of Sonoco (NYSE:SON) today increased its quarterly common stock dividend to $0.52 per share from the previous quarterly distribution of $0.51 per share. This new

SON